Sensorion

Corporate Presentation

Unlocking The Potential Of Advanced Therapies For Hearing Loss



May 2025

DISCLAIMER

- This document has been prepared by Sensorion (the “Company”) and is provided for information purposes only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness.
- This presentation does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of Sensorion in any jurisdiction.
- The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.
- The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.
- This document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information.
- This document contains certain forward-looking statements. These statements are not guarantees of the Company’s future performance. These forward-looking statements relate to the Company’s future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company’s future performance and the Company’s actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include those discussed or identified in the “Risk Factors” section of our 2024 Annual Report published on March 14, 2025, and available on our website (www.sensorion.com). Even if the Company’s financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company’s future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.
- Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables may not necessarily equal the sum of the individually rounded figures, amounts or percentages.
- All persons accessing this document must agree to the restrictions and limitations set out above.



1

SENSORION

Our vision is to help people with inner ear hearing disorders to live life with unlimited connections

Sensorion

Establishing Global Leadership In Hearing Loss With Strong And Diversified Pipeline

- **Unmet clinical need: 1.5bn people affected by hearing loss (HL)**
- **Multiple causes: genetic, environmental, idiopathic**

- **Modality agnostic approach to hearing loss disorders**
- **World-leading and exclusive partnerships**

- **Gene therapies (GT): SENS-501 and GJB2-GT**
- **Prospective Natural History Studies**

- **Small molecule SENS-401**
- **Multiple indications**

- **Multiple upcoming clinical milestones**

- **68 FTEs, listed on Euronext Growth**
- **Leading blue-chip life sciences shareholders**

Sensorion

Experienced Leadership Team, Board of Directors and SAB

NAWAL OUZREN
Chief Executive Officer

SENSORION
(Since 2017)

SHIRE
(2016-2017)
Head of the Global Genetic Diseases Franchise

GERALDINE HONNET
Chief Medical Officer

SENSORION
(Since 2020)

GENETHON
(2011-2020)
Director of Development

LAURENE DANON
Chief Financial Officer

SENSORION
(Since 2023)

JP MORGAN / JEFFERIES
(2005-2021)
Investment Banking / ECM

BERND SCHMIDT
Chief Technical Officer

SENSORION
(Since 2024)

QUELL Tx
(2019-2023)
SVP Product Delivery

STEPHANIE FILIPE
Head of Business Ops & Portfolio Management

SENSORION
(Since 2020)

CELLECTIS
(2016-2020)
Program Leader & Preclinical Manager

LAURENT DESIRE
Head of Preclinical Development

SENSORION
(Since 2020)

YPOSKESI
(2017-2020)
Head of Cellular & Molecular Biology Unit

Board Of Directors

- **Amit Munshi,** USA**,** Chairman and Independent Director
- **Nawal Ouzren**, France, Director, Sensorion
- **Khalil Barrage**, USA, Director, Invus
- **Julien Miara**, France, Invus
- **Cédric Moreau**, France, Sofinnova Partners
- **Natalie Berner,** USA, Redmile Group
- **John Furey**, USA, Independent Director
- **Eric de la Fortelle**, France, Independent Director
- **Aniz Girach**, UK, Independent Director
- **Florian Reinaud,** USA, Redmile group, Board Observer
- **Federico Mingozzi,** USA, Non-Executive Director

Scientific Advisory Board

- **Pr Christine Petit,** France, Chair SAB, Professor, Institut Pasteur
- **Pr Alain Fischer,** France, Professor, Collège de France
- **Dr. Robert Dow**, UK, Chief Medical Officer, Scendea
- **Dr. Paul Avan**, France, Head of the Center for Research, Hearing Institute (Paris)
- **Dr. Diane Lazard**, France, Principal Associate Investigator, Hearing Institute (Paris)
- **Dr. Hernán López-Schier**, Germany, Senior Group Leader & Research Unit Director at the Helmholtz Center (Munich)

Sensorion

Best-In-Class Partners And Internal Capabilities To Transform Standard Of Care

PARTNERS

TRANSLATIONAL RESEARCH

INSTITUT PASTEUR

CLINICAL RESEARCH

GLOBAL CLINICAL CENTERS OF EXCELLENCE

Necker ENFANTS MALADES HÔPITAL UNIVERSITAIRE

DIAGNOSIS AND PATIENT JOURNEY

Cochlear™

sonova HEAR THE WORLD

Sensorion

IN-HOUSE

- PRECLINICAL - SMALL MOLECULES & GT PROGRAMS
- CLINICAL EXPERIENCE
- CMC GENE THERAPY FACILITIES
- REGULATORY EXPERTISE
- PATIENT ACCESS

Sensorion

Portfolio Of Advanced Hearing Loss Therapies



3SBio has a right of first refusal with respect to licensing in Greater China of SENS-401 (except in combination with cochlear implants) and SENS-501 OTOF-GT

Option to grant a licence from the Institut Pasteur (licence granted for SENS-501, pre-defined financial terms and other terms to be negotiated for GJB2-GT)



2

GENE THERAPY PROGRAMS

Sensorion

Gene Therapy Programs Target Rare Auditory Diseases

FIRST PROGRAMS RESULTING FROM THE INSTITUT PASTEUR COLLABORATION

OTOFERLIN DEFICIENCY

- Pediatric patients with mutations in *OTOF* gene suffer from severe to profound sensorineural prelingual non-syndromic hearing loss
- Otoferlin deficiency could be responsible for up to 8% of all cases of congenital hearing loss
- Prevalence ~20,000 in the USA + EU
- Incidence ~1,100 per year in USA + EU
- EU and US Orphan Disease Designation, US Rare Pediatric Disease Designation
- Pediatric Investigational Plan Agreed in EU

GJB2-RELATED HEARING LOSS

We have identified three forms of hearing loss associated with *GJB2* gene mutations:

- Early onset of severe presbycusis (adult population)
- Childhood onset (pediatric population)
- Congenital onset (pediatric population)
- ~100,000 patients between 30- and 69-years old thought to be affected by a monogenic form of presbycusis due to GJB2 mutations
- Prevalence of congenital and childhood onset forms are estimated to be around 200,000 patients as around 50% of autosomal recessive non syndromic hearing loss cases are thought to be from *GJB2* mutations

Current Standard Of Care Is Cochlear Implantation

Gene Therapy Has A Life-Changing Potential For These Auditory Diseases

Sources: Akil et al. 2019 (link), Orphanet (link), company estimates based on publicly available population data Chardan 2020 report, Bryan, Garnier & Co 2019 report, Institut Pasteur, Boucher et al. 2020 (link)



2.1

OTOFERLIN DEFICIENCY

SENS-501

SENS-501 (OTOF-GT) Is The Perfect Pilot Program

- Well understood biology and pathology of the otoferlin deficiency
- Full functionality of the remaining hearing pathway components
- High specificity for the inner hair cells (IHCs), no off-target effect expected

- SENS-501 is the pilot program that has the potential to demonstrate that GT is a relevant medical approach for the inner ear
- SENS-501 will establish understanding of GT in the inner ear by the Regulators and the Payers for future GT programs
- Medical plausibility and target population have been confirmed through:
  - ✓ ODD in the US and EU, RPDD with eligibilty for voucher in the US
  - ✓ PIP agreed in EU
  - ✓ First cohort completed and DMC positive recommendation to move to the second dose



Adapted from Smith et al. Nature Medicine 2024

SENS-501

OTOF Gene Encodes Otoferlin, A Key Ca2+ Sensor Protein



***OTOF* is the gene coding for the otoferlin protein, a Ca2+ sensor key for vesicle fusion and vesicle pool replenishment at auditory hair cell ribbon synapses**

Otoferlin acts as a Ca2+ sensor for vesicle fusion and vesicle pool replenishment at auditory hair cell ribbon synapses) - Michalski et al 2017
Model illustrating calcium regulation of otoferlin/SNARE interaction in the hair cell – Adapted from Ramakrishnan et al. 2014

SENS-501

Long-Term Hearing Recovery In A Standardized Translational Model Of Otoferlin Deficiency

Long-Term Hearing Restoration

AAV-mOTOF injected in mice before hearing onset



Age of injection: PN10 (Post Natal D10)

- **Durable hearing restoration** in Otof-/- mice by dual AAV-OTOF directly delivered to the inner ear up to one year post-injection

Hearing Restoration Correlates With De Novo OTOF Expression

SENS-501 injected in mice after hearing onset
10 months after injection



****: p<0.0001; two-way ANOVA, Dunnett's Multiple comparison test with a single pooled variance

Age of injection: PN17-25



*O/IHC: Outer/Inner Hair Cells

- Both doses of SENS-501 demonstrated efficacy in **improving hearing in KO mice**
- SENS-501 leads to **otoferlin expression in Inner Hair Cells**

Olivier et al. ASGCT 2023

SENS-501

Restoration Of Efficient Sound Processing In Behavioural Test

Behavior Test Based On Hearing Recovery Implemented In Mouse



Olivier et al. ASGCT 2023

SENS-501
Dedicated Surgical Approach For Gene Therapy

Non-Human Primates injected through the round window membrane with or without stapedotomy

1 Fenestration



Used for cochlear implant

- Overpressure
- Limited volume
- Backflow
- Irregular transduction rate



2 Fenestrations



Combining 2 common surgical techniques: cochlear implant and stapedotomy

- No overpressure
- No backflow
- Homogenous and efficient transduction rate



Surgical Approach

- Surgical procedure is **similar to cochlear implantation and well mastered by ENT surgeons**
- Optimized surgery uses **stapedotomy procedure** to maximize target cells exposure along the full length of the tonotopic axis
- **Proprietary injection device developed** to inject a defined volume at a controlled flow rate

SENS-501

Raising The Bar With The SENS-501 Audiogene Study

Generating a compelling value story showing that SENS-501 treatment is able to:

- Demonstrate by itself **hearing restoration in toddlers**
- Enable infants to have **normal language acquisition** and **development**
- Improve **Patient Reported Outcomes & Quality of Life** to allow infants **social development**

Critical parameters leading Audiogene towards success:

- A **homogeneous** clinical study population in the right target age for **speech acquisition** (ie: below 3 years old)
- **No previous cochlear implantation** to be able to document the contribution of the GT in speech development
- **No concomitant cochlear implantation**
- Global clinical study **leveraging the natural history network**

SENS-501

Audiogene The First Phase 1/2 Study With A Homogeneous Population

Audiogene, a Phase 1/2 clinical trial in homogenous population of infants and toddlers, aged 6 to 31 months, naive of cochlear implants, to assess safety, tolerability, and efficacy of SENS-501 following unilateral injection into the cochlea



*Further participants may be recruited if required, who will be assessed in the same way as P7 to P12.

SENS-501
Audiogene Study Status

FIRST COHORT INJECTED

- **Patient recruitment going as planned with first cohort of infants and toddlers (three patients) injected in H2 2024**
- **In the first three patients so far, good initial safety:**
  - No dose-limiting toxicities, no Serious Adverse Events
  - Vestibular function and Otoacoustic Emissions (OAEs) remained intact and unchanged from baseline
  - Surgical administration procedure well tolerated
- **Efficacy data set being collected**

SECOND COHORT RECRUITING

- **Data Monitoring Committee provides positive recommendation to move to the second dose**
- **Ongoing Natural History Study OTOCONEX supports eligible patients' identification**

*IND: Investigational New Drug

SENS-501
Program Status

2.2

GJB2-RELATED HEARING LOSS

GJB2-GT

Leveraging SENS-501 Program For GJB2-GT Program Success

SENS-501 Is Paving The Way For GJB2-GT



Aiming To Develop Best-In Class And First-In Class Gene Therapy

- **AAV capsid selected for high-level of target cells specificity**
- **GT product showing high level of target cells transduction**
- **Limited off-target tissue biodistribution**
- **Surgical approach developed and mastered by ENT surgeons**

GJB2-GT

Connexin 26 Is Encoded By *GJB2* Gene And Is Responsible For Tissue Homeostasis

Mutations In The *GJB2* gene Lead To Deafness

- Connexin 26 and Connexin 30 proteins are the dominating connexins in the cochlea; heteromeric or heterotypic hexamers forming Gap Junctions
- Gap Junctions are key for the intercellular exchange of molecules (miRNA, glucose, ions, etc.) hence responsible for tissue homeostasis
- More than 100 recessive mutations origin Cx26 truncation / deletion leading to non-syndromic hearing loss and deafness, most are addressable via gene replacement
- Severity of hearing loss correlates with degree of loss of *GJB2* function



Schematic representation of a gap junction – adapted from Kemperman, Hoefsloot and Cremers J R Soc Med 2002;95; 171-177

GJB2 Expression In The Cochlea



- Supporting cells of the organ of Corti
- Fibrocytes of the spiral limbus and the lateral wall
- Intermediate and basal cells of the stria vascularis
- Not expressed in hair cells

GJB2-GT

Lead Candidate Was Selected To Answer Specific Development Criteria

CRITERIA	LEAD CANDIDATE
Natural and synthetic AAV capsid libraries screening for broad coverage of target cells	✓
Expression cassette design for high-level of target cells transduction, correct cellular localization, active gap-junctions	✓
Avoiding off-target expression (i.e. hair cells): promoter and regulatory sequences design	✓
Limited off-target tissue biodistribution	✓
Surgical approach developed and mastered by ENT surgeons	✓

Our Lead Candidate Was Designed to Ensure Broad Coverage of Relevant Cochlear Cells While Detargeting Hair Cells

GJB2-GT

Lead Candidate Can Deliver Connexin 26 In The Appropriate Target Cells

Correct Delivery Of Connexin 26 Using Lead Candidate Flag In Non-Human Primate Cochlea



Cell Types

Claudius Cells	✓
Deiters Cells	✓
Great Epithelial Ridge Cells	✓
Hensen Cells	✓
Inner Border Cells	✓
Inner Hair Cells	–
Inner Phalangeal Cells	✓
Pilar Cells	✓
Lateral Epithelial Ridge Cells	✓
Outer Hair Cells	–
Fibrocytes	✓
Stria Vascularis	✓

- No expression in Hair Cells confirmed
- No morphological defects observed 3 and 9 weeks after intracochlear administration

GJB2-GT

Lead Candidate Prevents Hearing Loss In Relevant Mouse Model

Proof Of Concept In Mice With Progressive Hearing Loss

Mouse model provides congenital and progressive hearing loss
(ABR threshold - 6 months after birth)



Progressive Model
Injected After Hearing Onset
ABR threshold - 10 weeks post-injection



Hearing Loss Prevention Correlates With Connexin 26 Expression

Lead candidate injected ear



Non injected ear



Left: Green staining demonstrates efficient Cx26 re-expression in target cells, which are otherwise depleted (right) in Cx26 in the *GJB2* deficient model

Proof Of Concept In Mice With Congenital Hearing Loss

Congenital model
ABR threshold - 7 weeks post-injection



Treated group *vs* Vehicle group: **** p<0.0001

- Mutant mice + Vehicle (n=7)
- Control mice + GJB2-GT (n=14)
- Best responders Mutant mice + GJB2-GT (n=7)

Average ABR measurements for the 7 best responder animals (selected for frequencies restored ≤ 60 dB)

- In **progressive model**: ongoing work indicates that hearing loss prevention correlates with Connexin 26 re-expression in target cells
- In **congenital model**: ongoing studies indicate that lead candidate GJB2-GT induced a statistically significant hearing recovery
  - as early as 3 weeks after injection
  - evidence of dose-response

Tran Van Ba et al., ESGCT 2024 (link)
More efficacy data on two additional models: *GJB2* gene therapy-response of two pre-clinical mouse models of the most frequent form of human deafness, DFNB1. Heritier et al., ESGCT 2024 (link)

GJB2-GT
Program Status





3

SENS-401 PROGRAMS

Multiple Indications To Treat And Prevent Hearing Loss

SENS-401
Mechanism Of Action



Trauma to inner ear can occur after **cochlear implantation**, exposure **to loud noise** or infection, head trauma or administration of **ototoxic drugs**

SENS-401 is the **(R)-enantiomer of Azasetron** belonging to the class of selective 5-HT3 Receptor (5-HT3R) antagonists with a calcineurin inhibition action

INSULT

Disrupted Ca2+ homeostasis
Excitotoxicity
Neuro Inflammation

Calcineurin Activation

Neurodegenerative cascades

- NFAT translocation: oxidative stress, survival, inflammation pathways
- Cell death pathways: BAD, mPTP, AIF, caspases activation
- Structural degeneration, swelling, synaptic uncoupling









3.1

SENS-401 CI

Preservation Of Residual Hearing Following Cochlear Implantation

CI

SENS-401 To Preserve Residual Hearing After Cochlear Implantation

COMBINATION OF COCHLEAR IMPLANT WITH SENS-401
TO PREVENT CELL-DEATH POST COCHLEAR IMPLANT PROCEDURE

BURDEN OF DISEASE

Growing understanding of the link between healthy hearing and healthy ageing

Source: Cochlear® 2018 investor day (link)

KEY FIGURES

80, 000

Implants sold globally in 2024[1]

$1.8bn

Cochlear implant market in 2020[2]

3%

Market penetration in adults eligible to CI in developed markets[1]

1. Cochlear ® FY24 Result Presentation (link)
2. Global Hearing, the highest growth hearing market, a primer on cochlear implants, Bernstein 2023

CI

Residual Low Frequency Hearing Benefits For Cochlear Implant Users

Initial shift*
(2-4 weeks postoperative)
between surgery and initial activation of the device

Attributed to perioperative factors

Second shift*
(3-6 months postoperative)

Attributed to intracochlear fibrosis, excitotoxic changes from electrical and acoustic stimulation

Postoperative hearing preservation defined as:
unaided air-conduction **thresholds < 85 dB HL** at 125, 250, and 500 Hz

*Jensen et al., Hearing Preservation After Cochlear Implantation, 2021

CI

Primary Endpoint of The Phase 2a Clinical Study For Residual Hearing Preservation Has Been Met

Perilymph Concentrations Data

	Treated with SENS-401 (n=16) n (%)
SENS-401 levels ≤ LLOQ	0
SENS-401 levels > LLOQ	14*(100)

*Among the 16 participants who underwent surgery, 15 have a perilymph samples and 14 samples were analyzable
*LLOQ define by a specific method developed for SENS-401

- **Presence of SENS-401 in the perilymph is confirmed in 100% of the patients** sampled following cochlear implantation
- **These results confirm that SENS-401 administered orally crosses the labyrinth barrier**

CI
SENS-401 CI Study Design - Study Completed

A Phase 2a, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph and to Assess Its Efficacy to Prevent Residual Hearing Loss After Cochlear Implantation



PRIMARY OBJECTIVE:
To evaluate the presence of SENS-401 in the perilymph

SECONDARY OUTCOME:
Change of hearing threshold from baseline to the end of the study in the implanted ear at several frequencies

CI

SENS-401 Provides Hearing Protection 6 & 14 Weeks Post-Cochlear Implantation

LS Mean change from baseline of hearing threshold values at 6 and 14 weeks post CI



500 Hz

Mean of the 3-frequency average (250-750 Hz) hearing threshold values at baseline, 6 weeks and 14 weeks post CI



Time

ANCOVA analysis and descriptive statistics used **p-value of 0.0567** for the PTA (250-750 Hz) suggested **a trend towards statistical significance**

- **Residual hearing loss is lower in patients treated with SENS-401 compared to control group 6 weeks after cochlear implantation**
- **This preservation effect is maintained 8 weeks after SENS-401 discontinuation (14 weeks post-CI)**

CI

SENS-401 Provides Residual Hearing Preservation* 6 & 14 Weeks Post-Cochlear Implantation



- Patients in the SENS-401 treated group are **twice as likely to show complete or partial hearing preservation** compared to control group after 7 weeks of continuous treatment
- Only SENS-401 treated group show a **complete hearing preservation with 40%** of treated patients compared to 0% in the control group at 6 weeks post-CI
- **These results are maintained 8 weeks** after SENS-401 discontinuation (14 weeks post-CI)

*Skarzynski H, van de Heyning P, Agrawal S, Arauz SL, Atlas M, Baumgartner W, et al. Towards a consensus on a hearing preservation classification system. Acta Otolaryngol Suppl. 2013(564):3-13.

CI

SENS-401 CI Final Results - Conclusion

- **SENS-401 can cross the labyrinthine barrier to target cochlear hair cells in all patients sampled, confirming primary endpoint is met**. **SENS-401, present in the perilymph fluid, reaches concentrations that are pharmacologically active.**
- A **complete hearing preservation** is exclusively observed in 40% of patients treated with SENS-401 at 6 weeks post cochlear implantation.
- Eight weeks after discontinuation of SENS-401, the **hearing protective effect is maintained.**
- **Residual hearing loss is reduced in the SENS-401 treated group** compared to the untreated group at 6 weeks post-cochlear implantation.
- SENS-401 taken for 8 weeks confirms it has a **good safety profile.**
- **SENS- 401 has the potential to modify the outcome of CI while preserving residual hearing by improving speech perception in quiet and noise, music perception, spatial localization and maintaining more natural sound quality.**
- These results support the SSNHL phase 2 data and further development of SENS-401.



3.2

SENS-401 CIO

Prevention Of Cisplatin-Induced Ototoxicity

CIO

Cisplatin Administration For Chemotherapies Damages The Inner Ear And Leads To Hearing Loss, Tinnitus And Dizziness

WHAT IS CIO?

Hearing loss caused by cisplatin administration as chemotherapeutic treatment.

Risk factors include young age as well as individual and cumulative cisplatin doses.

CIO leads to permanent inner ear problems in 40-60%[1] of adult cases and up to 90% of pediatric cases.

These complications significantly impact patients' quality of life due to:

- Hearing loss, tinnitus and dizziness impacting daily life activities
- Problems in language acquisition and learning for pediatric patients
- Difficulties in communicating, social isolation, cognitive decline

Potential treatments must not interfere with cisplatin efficacy.

Number of total treated patients by Cisplatin per year: 1 140 000 in G7 countries[2]

[1] JCO Oncology practice, ASCO, volume 19, Issue 5/ CIO: a concise review of the burden, prevention and interception strategies, May 2024 Chattaraj
[2] Globocan 24

CIO

SENS-401 Phase 2a Proof-Of-Concept Study NOTOXIS
Recruitment Completed – Positive Preliminary Safety Data

A Phase 2a, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects with a Neoplastic Disease



Primary Endpoint (4 weeks after the last cisplatin dose)

- Maximum change from baseline in Pure Tone Audiometry (PTA) across three consecutive frequencies within the 0.5-12.5 KHz range

Secondary Endpoints (4 and 12 weeks after the last cisplatin dose)

- Maximum change from baseline in Pure Tone Audiometry (PTA) across three consecutive frequencies within the 0.5-12.5 KHz range
- CTCAE grading
- Change from baseline of speech discrimination score (noise & quiet)
- Change from baseline in THI questionnaires

CIO

Preliminary Results Show Patients With High Exposure To Cisplatin May Benefit The Most From SENS-401's Otoprotective Effects



Groups	n	Variables	Mean	SD
Control	9	Cisplatin dose	305	110.0
		PTA change	26	13.6
SENS-401	7	Cisplatin dose	342	98.7
		PTA change	24	11.7

- SENS-401 subjects were exposed to significantly more cisplatin than control
- Hearing loss is similar between SENS-401 and control group

- As the cumulative dose of cisplatin increases, severity of ototoxicity observed in the control group escalates *r=0.42*
- **Benefit of SENS-401 increases with higher cisplatin doses**
- **SENS-401 treatment group outperforms the control group at cisplatin doses > 300 mg/m²**

CIO
Key Takeaways From Preliminary Study Data

- **Cumulative dose** of cisplatin is a **key factor** of ototoxicity severity.
- SENS-401 has a **favorable safety profile** when administered continuously for up to **23 weeks** in adult patients undergoing cisplatin-based chemotherapy.
- Based on preliminary data, **no significant difference** observed on ototoxicity measured by **PTA change** or CTCAE grading, **however SENS-401 treated group received higher cumulative dose of cisplatin compared to control.**
- Patients with **higher exposure to cisplatin may benefit the most from SENS-401's otoprotective effect.**
- **The preliminary results suggest a trend toward an otoprotective effect of SENS-401 beyond a cisplatin dose of 300 mg/m^2.**
- Recruitment completed; 48 patients randomized; follow-up ongoing

CI & CIO

SENS-401 Programs Status

SENS-401 with cochlear implants
-
Full Data Readout
Sept 20, 2024

SENS-401 CIO NOTOXIS
-
Preliminary Safety and Efficacy Data

SENS-401 with cochlear implants
-
Final Results

SENS-401 NOTOXIS
-
End of Enrollment
H1 2025

SENS-401 NOTOXIS
-
Topline Data
End of H2 2025

Sensorion Newsflow [Estimated Timelines]

SENS-501 Gene Therapy Program

H1 2025
Audiogene 2nd cohort enrollment completion

GJB2-GT Program

Q1 2026
Clinical Trial Applications

SENS-401 Program

H2 2025
CIO NOTOXIS: Topline Data

Sensorion
Conclusion

- **Developing hearing loss therapeutics to treat, prevent and restore hearing – an area of high unmet clinical need**

- **Combining extensive internal capabilities with world-leading exclusive partnerships**

- **Advancing a robust and diversified pipeline with multiple upcoming milestones in 2025**

- **Completion of patient recruitment of the second cohort in Audiogene in H1 25**
- **SENS-401 CIO Ph2a topline data by end of H2 25**
- **Clinical Trial Application for GJB2-GT in Q1 2026**

THANK YOU

E:contact@sensorion-pharma.com



HEARING LOSS

Access And Clarity Are Mandatory For Optimal Outcomes



O = Right ear threshold
X = Left ear threshold

Hearing aid fitting range*

Cochlear implant candidacy range*



*Guideline criteria may vary slightly by manufacturer, device, and/or country

Image of hearing aid: https://commons.wikimedia.org/wiki/File:Unitron_Ziel_photo_2.jpg
Image of cochlear implant sound processor on ear: https://commons.wikimedia.org/wiki/File:Cochlear_Nucleus%C2%AE_7_Sound_Processor.jpg



Internal Capabilities

We Have Established Internal Capabilities To Ensure Successful Execution

PRECLINICAL - SMALL MOLECULES & GT PROGRAMS

- Audiology, inner ear surgery and drug administration expertise in preclinical models
- Technology&Innovation Platform: assay development and gene therapy vectors design
- Cell Model and Animal Pharmacology Platforms: from target & drug discovery, to POC/dose-finding studies in disease-relevant models

CLINICAL EXPERIENCE

- 600 subjects enrolled in Sensorion led clinical trials
- Set-up audio tests in different countries, languages
- In-house audiology expertise of more than 20 years for the pediatric and adult populations and cochlear implants
- Development of gene therapy products in several rare diseases

CMC GENE THERAPY FACILITIES

- Process development: non-GMP manufacturing from small scale up to 50L in bioreactor
- Analytical development: development of product-specific analytical methods, in-house generic assays to support process development and AAV manufacturing

REGULATORY EXPERTISE

- Develop regulatory strategies to ensure expedited product development including gene therapy
- Regulatory Agencies interaction (EU/US)
- Shape the treatment guidelines and standardize clinical endpoints

PATIENT ACCESS

- Working with prominent payers from the EU5
- Obtaining consultation about our early Clinical Development Program within EU and US
- Building capabilities cross-functionally



SENS-401 PROGRAMS Back-Up

Multiple Indications To Treat And Prevent Hearing Loss



SSNHL

Sudden Sensorineural Hearing Loss

Sudden Sensorineural Hearing Loss (SSNHL) is a Severe Disease Affecting more than 200,000 Patients Per Year

WHAT IS SSNHL?

The sudden onset of a significant hearing loss due to dysfunction of the cells of the cochlea and central auditory structures.

Hearing loss develops over less than 72 hrs, hearing sensitivity is reduced by at least 30 dB (1,000 fold) in the affected ear(s).

>90%[1] of cases are idiopathic, known causes include noise/head trauma, ischemia, infection.

>33%[2] of patients suffer from permanent disabling hearing loss, mostly those with initial severe/profound hearing loss.

Complications significantly impact quality of life due to:

- Difficulties in communicating, social isolation, cognitive decline
- Accompanying tinnitus

Incidence: 27-35 per 100,000[3] to 160[4] per 100 000 e.g > 200,000 patients in 2017 in G7 countries[5]



1. American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) Clinical Practice Guidelines
2. Kearney Interviews
3. Incidence of SSNHL - OTOL Neurotol. 2013 Dec, T. Alexander & J. Harris, OTOL Neurotol
4. A present investigation of the epidemiology in idiopathic sudden sensorineural hearing loss] [Article in German] E Klemm 1, A Deutscher, R Mösges
5. Company estimates based on publicly available data (in the US, Japan, Germany, France, the UK, Italy and Spain)

SSNHL
AUDIBLE-S Phase 2 Design

A Phase 2b, Multicenter, Randomized, Controlled, Double-blind Study to Evaluate the Efficacy of SENS-401 to Treat Patients with Severe to Profound Sudden Sensorineural Hearing Loss

50 clinical sites globally

1 Primary endpoint
Audiometry
15 dB improvement
vs. Placebo

115 patients enrolled

Timing

Q1 2019 center openings

June 20 & Jan 21 Positive DSMB Review

Q1 2022 Final results



Primary endpoint definition:
"…change in pure tone audiometry (PTA); average of the hearing threshold of 3 contiguous most affected hearing frequencies in decibels in the affected ear from baseline to the end of treatment visit (Visit 5/D28±3)"

SSNHL

SENS-401 Induces Complete PTA Recovery In 50% Of Patients

COMPLETE PTA RECOVERY



Complete PTA recovery (n/n total)	Placebo	SENS-401 (2 doses pooled*)
Day 28	9/28	25/49
Day 84	8/26	22/40

*As SENS-401 plasmatic concentration is similar for the two tested doses, the results have been pooled.

- **Complete hearing recovery** is defined as patients with hearing loss at baseline who will **revert to PTA < 20 dB,** considered as *"normal"* hearing
- SENS-401 is statistically superior to placebo at Day 84 ($p<0.05$)

SSNHL
Phase 2 Results Summary

Complete PTA recovery is achieved in 50% of the SENS-401 treated patients.

SENS-401 shows a **clinically meaningful and statistically significant effect on PTA change** (at least 10 dB) over time in a **large homogeneous idiopathic population of patients treated with corticosteroids.**

SENS-401 induces a **significative PTA change of at least 19 dB at day 28 and up to 25 dB at Day 84 allowing a reduction of the hearing loss degree from profound to mild, in large profound hearing loss sub-group.**

A better response was observed in both treatment groups with a **continuous improvement between Day 28 and Day 84.**

The change in PTA translates into functional improvement evidenced with speech audiometry tests.

Responder rate is always better in the treated group compared to placebo and difference with placebo increases over time.

Safe and well tolerated in 115-patient SSNHL study; although primary endpoint not met data supports and informs further clinical development.